Uma das principais biofarmacêuticas globais
Mais rápido até o pico de receita
Receita herdada preservada
À frente da meta de lançamento
Desafio
Diante do fim de patentes de dois blockbusters, precisava acelerar lançamentos oncológicos de nova geração e maximizar receita das marcas maduras em 30 mercados.
Abordagem
We redesigned the go-to-market model around omnichannel engagement, deploying AI-driven physician targeting and next-best-action engines. We restructured the commercial organization from geography-based to therapeutic-area-aligned teams and built a launch excellence playbook that reduced time-to-peak-revenue by 40%.
Impacto
The first new therapy launched reached peak-year revenue projections 18 months ahead of plan. Legacy brand managed decline was slowed by 25%, preserving $1.2 billion in cumulative revenue over three years.